Toggle navigation
Publications
Researchers
Institutions
0
Sign In
Federated Authentication
(Click on the image)
Local Sign In
Password Recovery
Register
Sign In
David Scott Miller
AuthID:
R-00K-250
Publications
Confirmed
To Validate
Document Source:
All
Document Type:
All Document Types
Article (259)
Proceedings Paper (14)
Review (13)
Unpublished (12)
Book Chapter (7)
Letter (4)
Note (4)
Editorial Material (3)
Correction (1)
Year Start - End:
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
-
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
Order:
Year Dsc
Year Asc
Cit. WOS Dsc
IF WOS Dsc
Cit. Scopus Dsc
IF Scopus Dsc
Title Asc
Title Dsc
Results:
10
20
30
40
50
Confirmed Publications: 317
1
TITLE:
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS:
Jung Min Lee; Austin Miller; Peter G Rose; Mariam Alhilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel;
David Scott Miller
; Elizabeth E Hopp; Andrea O’shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED:
2025
,
SOURCE:
Clinical Cancer Research,
VOLUME:
31,
ISSUE:
12
INDEXED IN:
Scopus
CrossRef
IN MY:
ORCID
2
TITLE:
Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS:
Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel;
David Scott Miller
; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED:
2025
INDEXED IN:
CrossRef
IN MY:
ORCID
3
TITLE:
E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).
AUTHORS:
Jung-Yun Lee; Kosei Hasegawa; Byoung-Gie Kim; Barry S Berman; Shiro Suzuki; Bradley Corr; Mayu Yunokawa; Douglas Orr; Noboru Yamamoto; Pamela T Soliman;
David Scott Miller
; Takatoshi Sahara; Lea Dutta; Jincao Wu; Jodi McKenzie; Vicky Makker;
PUBLISHED:
2025
,
SOURCE:
Journal of Clinical Oncology,
VOLUME:
43,
ISSUE:
16_suppl
INDEXED IN:
CrossRef
IN MY:
ORCID
4
TITLE:
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
AUTHORS:
Daniela E Matei; Danielle M Enserro; Marcus E Randall; David Mutch; William Small; Paul A Disilvestro; Nick M Spirtos; David M O'Malley; Guilherme H Cantuaria; David Michelin; Steven Waggoner; Mark Shahin; Saketh Guntupalli; Olivia Lara; Frederick R Ueland; David Warshal; Albert Bonebrake; Krishnansu S Tewari; Annie Tan; Matthew A Powell;
Joan L Walker;
Alessandro D Santin;
Jong Hyeok Kim;
David Scott Miller
;
...More
PUBLISHED:
2025
,
SOURCE:
Journal of Clinical Oncology,
VOLUME:
43,
ISSUE:
9
INDEXED IN:
Scopus
CrossRef
IN MY:
ORCID
5
TITLE:
Molecular Classification of Endometrial Cancers (EC) and Association with Relapse-Free Survival (RFS) and Overall Survival (OS) Outcomes: Ancillary Analysis of GOG-0258
AUTHORS:
Aine Clements; Danielle Enserro; Kyle C Strickland; Rebecca A Previs; Daniela E Matei; David G Mutch; Matthew A Powell; Ann H Klopp;
David Scott Miller
; William Small Jr.; Paul DiSilvestro; Nick M Spirtos; Casey Cosgrove; Greg Sfakianos; Rebecca R Liu; Roberto Vargas; Mark Shahin; Bradley R Corr; Kimberly Dessources; Frederick Ueland;
David Warshal;
Jessica Gillen;
Angeles Alvarez Secord;
...More
PUBLISHED:
2025
INDEXED IN:
CrossRef
IN MY:
ORCID
6
TITLE:
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Full Text
AUTHORS:
Clements, A; Enserro, D; Strickland, KC; Previs, R; Matei, D; Mutch, D; Powell, M; Klopp, A;
David Scott Miller
; Small, W Jr; Disilvestro, P; Spirtos, N; Cosgrove, C; Sfakianos, G; Liu, JR; Vargas, R; Shahin, M; Corr, B; Dessources, K; Ueland, F;
Warshal, D;
Gillen, J;
Secord, AA;
...More
PUBLISHED:
2025
,
SOURCE:
GYNECOLOGIC ONCOLOGY,
VOLUME:
193
INDEXED IN:
Scopus
WOS
CrossRef
Unpaywall
IN MY:
ORCID
7
TITLE:
Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol
AUTHORS:
Koji Matsuo; Danielle M Enserro; Jason D Wright; Lynda D Roman; Matthew A Powell;
David Scott Miller
; Christa I Nagel; Premal H Thaker; Robert S Mannel; Ashley R Stuckey; Saketh R Guntupalli; Paniti Sukumvanich; Melissa A Geller; Roberto Vargas; Gottfried E Konecny; David P Warshal; Krishnansu S Tewari; Nick M Spirtos; Bhavana Pothuri; William T Creasman;
David G Mutch;
...More
PUBLISHED:
2025
,
SOURCE:
Gynecologic Oncology,
VOLUME:
201
INDEXED IN:
Scopus
IN MY:
ORCID
8
TITLE:
Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS:
Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel;
David Scott Miller
; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED:
2025
INDEXED IN:
CrossRef
IN MY:
ORCID
9
TITLE:
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS:
Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel;
David Scott Miller
; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED:
2025
INDEXED IN:
CrossRef
IN MY:
ORCID
10
TITLE:
Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
AUTHORS:
Jung-Min Lee; Austin Miller; Peter G Rose; Mariam AlHilli; Christina Washington; Veena S John; Chirag A Shah; Koji Matsuo; Jean Siedel;
David Scott Miller
; Elizabeth E Hopp; Andrea O’Shea; John K Chan; Leslie S Bradford; Christopher B Morse; Christa I Nagel; Kerry J Rodabaugh; Elise C Kohn; Kathleen N Moore; Joyce F Liu;
PUBLISHED:
2025
INDEXED IN:
CrossRef
IN MY:
ORCID
Add to Marked List
Check All
Export
×
Publication Export Settings
BibTex
EndNote
APA
CSV
PDF
Export Preview
Print
×
Publication Print Settings
HTML
PDF
Print Preview
Page 1 of 32. Total results: 317.
<<
<
1
2
3
4
5
6
7
8
9
>
>>
×
Select Source
This publication has:
2 records from
ISI
2 records from
SCOPUS
2 records from
DBLP
2 records from
Unpaywall
2 records from
Openlibrary
2 records from
Handle
2 records from
DataCite
Please select which records must be used by Authenticus!
×
Preview Publications
© 2025 CRACS & Inesc TEC - All Rights Reserved
Privacy Policy
|
Terms of Service